Send to

Choose Destination
Cancer Discov. 2019 Feb 8. doi: 10.1158/2159-8290.CD-RW2019-016. [Epub ahead of print]

Ibrutinib plus Palbociclib Has Efficacy in Mantle Cell Lymphoma.

[No authors listed]


The BTK inhibitor ibrutinib plus the CDK4 inhibitor palbociclib achieves responses in 67% of MCL patients.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center